Anti-infliximab Antibodies with Neutralizing Capacity in Patients with Inflammatory Bowel Disease

Abstract

Detection of neutralizing antibody activity was superior to antibody quantization by enzyme-linked immunosorbent assay with respect to correlation with clinical LOR, and for prediction of subsequent LOR. These findings may assist in optimizing infliximab therapy in patients with inflammatory bowel disease.